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a b s t r a c t
Considerable advances have been made in treatment of acute lymphoblastic leukemia
(ALL) with an overall survival rate of 85% in children, and with a great improvement in
adults. Despite this improvements and the accessibility of hematopoietic stem cell trans-
plantation, relapsed ALL remains a leading cause of childhood mortality emphasizing the
need of new approaches on therapy. Understanding of the pathobiology and genetic
alteration of ALL has been enhanced by developing molecular technologies including
microarray analysis and genome sequencing. These studies have helped identifying
mutations in key signaling pathways and revolutionized the treatment of ALL by drugs
which specifically target the genetic defects of leukemia cells, such as tyrosine kinase
inhibitors. In this paper, we review the clinically important Genetic Alterations in ALL.
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Acute lymphoblastic leukemia (ALL) is the most common
cancer in children, with top prevalence in the ages of 2–5
years and the important cause of mortality from hematolo-
gical cancers in adults with second peak after the age of 50
years [1, 2]. Totally children with B linage ALL have
a favorable clinical outcome in comparison with those
suffering from T linage ALL [3]. Considerable advances have
been made in treatment of ALL with an overall survival rate
of 85% in children [2]. About adults, the outcome is being* Corresponding author at: Stem Cell Research Center, Imam Reza 
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z o.o. All rights reserved.improved but it remains poor compared to children with
a long- term survival of only 45% [1]. The reasons for these
differences are multifactorial and not fully understood, but
with increasing age, the frequency of genetic alterations
with favorable outcome decreases and alteration with poor
outcome like BCR-ABL are more common [2]. Although, all
chromosomal translocations is occurred in any age and in
both children and adults but there is a significant difference
in the incidence of approximately most subgroups based on
age (Fig. 1) [4]. For instance ETV6- Ranx1 and hyperdiploidy
dominate in young children, with low incidence of this
rearrangement in adults (3%,), whereas the incidence ofHospital, Tabriz University of Medical Sciences, Daneshgah St.,
w, Instytut Hematologii i Transfuzjologii. Published by Elsevier Sp.
Fig. 1 – Distribution of ALL subtypes according to age groups. The occurrence of ALL. Subtypes varies between age groups.
Abbreviations: ALL, acute lymphoblastic leukemia; B-other, B-cell acute lymphoblastic leukemia with other subtypes; CRLF2-
r, CRLF-2-rearranged; MLLr, MLL-rearranged; Ph-like, Philadelphia chromosome-like [68, 69]
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with age, 3% in children versus 25% in adult [4]. This
biological difference highly likely affects outcome and over-
all survival in adults which is significantly inferior to
children.
Primary genetic subtypes of B-cell precursor ALL
The fundamental mechanisms of leukemia transformation
are the same and contain, abnormal expression of proto-
ancogen and chromosomal translocation that finally create
fusion genes encoding active kinases and transformed
transcription factors. Such abnormalities cause ALL by
enforcing in lymphoid progenitor cells an unrestrictedTable I – Clinically relevant subgroups of ALL
Chromosomal translocations/gene fusions Prevalen
High hyperdiploidy with more than 50 chromosomes 30 
Hypodiploidy with less than 44 chromosomes 2–3 
t(9;22)(q34;q11.2) translocation encoding BCR–ABL1 fusion 2–4 
t(12;21)(p13;q22) translocation encoding ETV6–RUNX1 fusion 15–25 
t(4;11)(q21;q23) translocation encoding MLL–AF4 fusion 1–2 
t(1;19)(q23;p13) translocation encoding TCF3–PBX1 fusion 2–6 
Ph-like ALL 10–15 ability for self-renewal, which typically followed by lacking
of control on normal proliferation, a block in cell differentia-
tion and almost resistance to normal apoptosis [5]. The
gross chromosomal alterations are hallmark of ALL, and the
occurrence of each alteration varies with age (Tab. I). The
most common rearrangements observed in B-lineage ALL
are the t(12;21) (p13;q22) rearrangement resulting in the
expression of TEL-AML1 fusion, the t(9;22) (q34;q11.2) “Phila-
delphia” chromosome resulting in the expression of BCR–
ABL1 fusion, the t(1;19) (q23;p13) translocation resulting in
the expression of TCF3–PBX1 fusion; and t(4;11) (q21;q23)
translocation encoding MLL–AF4 fusion. Identification of
these rearrangements is important in diagnosis and risk
stratification of patients with ALL. Two main genetic sub-
types TEL-AML1 (ETV6-RUNX1) positive and hyperdiploidyce (%) Relative prognosis
Excellent
Poor





Multiple cytokine receptor and kinase-activating lesions;
amenable to tyrosine-kinase inhibitor therapy
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common abnormalities (approximately 50%) in pediatric
precursor B-ALL cases. Both of them have favorable outcome
and are classified in good risk cytogenetic abnormalities
most likely due to sensitivity of TEL-AML1 to L-asparaginase
and hyperdiploidy to L-asparaginase and antimetabolites
such as 6-mercaptopurine and methotrexate [3, 6, 7]. While
in adults, the most common genetic abnormalities is Phila-
delphia chromosome translocation t (9:22) BCR-ABL1, which
encodes the activated BCR-ABL1 tyrosine kinase. It is
a reciprocal translocation between chromosome 9 and 22
which fuses the ABL1 oncogene on chromosome 9, to
a breakpoint cluster region (BCR) from chromosome 22 and
is related to a high risk of relapse. Other abnormalities with
high risk of relapse and poor outcome are rearrangement of
mixed-linage leukemia genes (MLL) in both groups.
The protein with histone methyl transference activity,
which is encoded by MLL gene is essential for hematopoietic
regulation of HOX-A and MEISI gene expression. The most
common gene rearrangements include t(4;11) encoding MLL-
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19% of relapsed B and t(10;11) encoding MLL-MLLT10,between mentioned rear-
rangements the t(4;11) translocation is the most common
with 50% incidence. In general, MLL rearrangements are
related with adverse outcome highly likely due to cellular
drug resistance [8]. Of note, “BCR-ABL1-like” or “Ph.-like” ALL,
is a newly described subtype of high risk ALL that is related
with poor outcome, and increased in frequency with age
(which will be described in more details in the following
section) [9].
Submicroscopic genetic aberration in ALL
Primary oncogenic events such as chromosomal rearran-
gements are not sufficient to cause leukemia by them-
selves and secondary mutations should accompany this
chromosomal translocation. Advances in cytogenetic uti-
lizing array based technology have revealed additional
submicroscopic abnormalities in genes that are involved
in normal hematopoiesis, apoptosis and tumor suppres-
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Associated with poor outcome in both
BCR-ABL1–positive and negative ALL
cases
[40, 44]
Transcription factor required for B-
lymphoid development; mutations
impair DNA binding and
transcriptional activation but not
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Activation of kinase signaling
pathways and associated with
increased risk of relapse
s In B –ALL is associated with the
aberrant expression of CRLF2, results
in receptor dimerization with CRLF2
and JAK-STAT activation, may be
responsive to JAK inhibitors
[61–64]
ll ALL and mutants confer resistance to





Associated with disease relapse and
poor event-free survival and overall
survival.
[66]
–AL Mutations result in impaired histone
acetylation and transcriptional
regulation and associated with
glucocorticoid resistance
[67]
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ALL (CRLF2)
CRLF2 rearrangement has been detected in approximately
5–15% of childhood and adult B-cell precursor and also
they are more common in Down syndrome ALL (in 50% of
cases) [10–12]. CRLF2 encodes cytokine receptor like factor
2 (also known thymic stromal lymphopoitin receptor/
TSLPR) which forms a heterodimeric receptor for thymic
stromal lymphopoitin (TSLP) with interleukin-7 receptor-
alpha (IL7R) [13]. Two alterations have been typically
recognized in CRLF2; a chromosomal translocation which
juxtaposes CRLF2 to the immunoglobin heavy chain locus
(IGHG) or more commonly a focal deletion upstream of
CRLF2 resulting in fusion of CRLF2 gene with G protein-
coupled puringic receptor P2Y8 gene (P2RY8) [14]. While the
P2RY8-CRLF2 alteration is more common in younger pedia-
tric ALL, but IGH- CRLF2 is frequently detected in adults
with ALL [12, 15]. Both of the rearrangements result in
overexpression of CRLF2 on the cell surface of leukemia
lymphoblast which can be detected by flowcytometry [12].
Less commonly alteration of CRLF2 is a point mutation at
codon 232 which replace a phenylalanine with a cysteine.
Various groups have tried to describe prognostic value of
CRLF2 alteration and also its association with treatment
outcome in patients with ALL. It has been shown that
Patients with a high CRLF2 expression had a high rates of
relapse (31%  8% vs 11%  1%, P = 0.006) and a poor event
free survival (EFS) (61%  8% vs 83%  2%, P = 0.003) com-
pared to Patients with a low CRLF2 expression [16]. In
a cohort study, it was shown that ALL Patients with
overexpression of CRLF2 have a very poor outcome [17].
Another cohort study of pediatric ALL reported that there
is a high occurrence of CRLF2 genomic lesions in DS-ALL
(in more than 50% of cases) [11]. Additionally, shRNA
knockdown of CRLF2 in B-ALL cell lines only partly inhib-
ited cell growth [15], which suggest that CRLF2 overexpres-
sion alone is not sufficient to transform cells and other
cooperating mutations and covariates may be involved.
The best described of this covariates that accompany
CRLF2 alteration are involving janus kinase1 and januse
kinase 2 mutations, IKZF1 mutations and DS-ALL. Half of
patients with CRLF2 overexpression also harbor JAK muta-
tions (JAK 1 and JAK 2) [17]. Mutation in the pseudokinase
domain of JAK2 at R683 is the most common [18]. CRLF2
rearrangement together with JAK2 mutants resulted in
constitutive JAK-STAT activation and cytokine-independent
cell growth [11]. It was revealed that in 41 CRLF2-rear-
ranged DS-ALL patients, 34% of them also had JAK2
mutations [11]. In line, in study of 26 high-risk pediatric B-
ALL patients with CRLF2 overexpression, 69% of them had
JAK mutations [19]. CRLF2 rearrangements also have
revealed to be associated with gain of function mutations
of IL7R in patients with ALL [20, 21]. The mutant IL-7R
proteins forms a functional receptor with CRLF2 for TSLP
and resulting in cytokine-independent growth of progeni-
tor lymphoid Cells [20]. Importantly, CRLF2 rearrangements
are surrogates of poor outcome and can be used in risk
stratification and targeting therapy.IKZF1 gene deletions
During recent years, between recurring genetic alterations
which cooperate in leukemogenesis, the lymphoid transcrip-
tion factor gene IKZF1 has been found to have definite
prognostic impact in B-ALL [22, 23]. IKZF1, which encodes
IKAROS protein member of family of zinc finger, is required
for the development of all lymphoid lineages [24] and has
been established as one of the most clinically relevant
tumor suppressors in high-risk acute lymphoblastic leuke-
mia. IKZF1 deletions usually result in the expression of
dominant-negative IKAROS variants (e.g., IK6) that are
characterized by loss of N-terminal zinc fingers (which
mediate DNA binding) and result in the loss of the tumor
suppressor function attributed to wild-type IKZF1 [25, 26].
The incidence of IKZF1 deletions in children with Philadel-
phia chromosome-positive (Ph+) ALL is approximately 70%,
whereas its incidence in children with Philadelphia chromo-
some–negative (Ph-) ALL is 10–15%, and is related with an
increased risk of relapse and decreased overall survival in
both groups [24, 27–30].
Intrachromosomal amplifications of chromosome
21 (iAMP21) in ALL
Intrachromosomal amplification of chromosome 21 (iAMP21)
is an uncommon high-risk Chromosomal abnormality that
occur in approximately 2–5% of pediatric patients with B-cell
precursor ALL [31–33]. Fluorescence in situ hybridization
(FISH), using RUNX1, provides the only reliable detection
method (five or more RUNX1 signals per cell) [34]. Patients
with iAMP21 are older (median 9 years vs 5 years) with
a low white cell count (median 3.9 vs 12.4) compared to
children without this abnormality [35]. In a study of, 1630
ALL patients were treated on the UK MRC ALL97 protocol,
iAMP21 was recognized as an independent predictor of poor
EFS (29% vs 78%) and OS (71% vs 87%) at 5 years [35]. The
results of two cohorts of patients with B-cell precursor ALL
and iAMP amplification (2%) treated on ALL97 or UKALL2003
showed that iAMP21 patients with ALL benefitted from
receiving more intensive therapy in UKALL2003 (event-free
survival (29% vs 78%), relapse (70% vs 16%) and overall
survival rates (67% vs 89%) at 5 years) [36].
BCR-ABL1-like or “Ph-like” ALL
Ph-like ALL, is a newly described subtype of ALL which
exhibit a gene expression profile similar to that of Ph+ ALL
but lacks BCR-ABL1 fusion gene [37–39]. Deletions or muta-
tions of IKZF1 are hallmark of both BCR–ABL1–positive and
Ph-like ALL which strikingly is associated with treatment
failure and disease relapse in both [7, 30, 38, 40] The
incidence of Ph-like ALL increases with age, from 10–15% of
childhood B-ALL to over 25% of ALL in young adults (Fig. 1).
The prognosis of BCR-ABL1–like ALL is poor. In the COG
AALL0232 study, the EFS of the BCR ABL1–like cases was
significantly inferior to that of the non BCR-ABL1 like cases
Table III – Kinase rearrangements and therapeutic targets
in Ph-like ALL [9]














a c t a h a e m a t o l o g i c a p o l o n i c a 4 8 ( 2 0 1 7 ) 1 0 – 1 714(62.6%  6.9% vs. 85.8%  2.0%) [41]. Rearrangements and
sequence mutations in several classes of cytokine receptors
and tyrosine kinases are a hallmark of Ph-like ALL [42].
Kinase-activating alterations were identified in 91% of
patients with Ph-like ALL; rearrangements involving ABL1,
ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP,
or TYK2 that are responsive to treatment with currently
available TKIs (Tab. III) [9].
PAX5
The PAX5 gene, belongs to the paired box (PAX) gene family
of transcription factors, crucial for B lymphoid cell commit-
ment [43]. Somatic alterations of the PAX5 are a hallmark of
B-ALL and occurred in over one – third of this patients
[44, 45]. These alterations are heterozygous and comprise
focal deletions, translocations, or point mutations that
disrupt PAX5 DNA-binding or transcriptional regulatory
functions [46]. Several studies showed that PAX5 abnormal-
ities were not associated with an unfavorable prognosis and
are not associated to outcome [44, 46]. Also in study of 89
patients with ALL, deletions of PAX5 was observed in 29
patients which had no prognostic significance in ALL [47].
Janus kinase 1 and 2 mutations (JAK1 or JAK2) and
JAK-STAT pathway in ALL
Janus kinase (JAK) is a family of intracellular, non-receptor
tyrosine kinases that transduce cytokine-mediated signals
via the JAK-STAT pathway [48, 49]. The JAK family has four
members:JAK1, JAK2, JAK3, and TYK2 that functioning as
signal transducers to control cellular proliferation, survi-
val, and differentiation [49]. The incidence of JAK mutation
in ALL has been reported to be about 18 [50, 51] to 35% in
DS-ALL [52] and about 10% in high risk BCR-ABL1 negative
ALL and have been associated with poor outcome [18].
Notably, between other family members, JAK2 mutations
are more common (at or near JAK2 R683) in B-progenitor
ALL [18, 50]. Importantly, JAK mutations were shown to be
associated with CRLF2 rearrangements, it has been shownthat 70% of CRLF2-rearranged cases also harbor JAK muta-
tions [19]. Over expression of CRLF2 with JAK2 mutants
resulted in cytokine-independent cell growth and constitu-
tive activation of JAK-STAT signaling pathway, demonstrat-
ing that these two genetic lesions together contribute to
leukemogenesis in B-progenitor ALL [19]. The signal trans-
ducers and activators of transcription (STAT) family is one
of the best characterized downstream that is activated by
JAK signaling. It contains a number of latent transcription
factors that, when phosphorylated by the JAKs, drive the
expression of genes involved in proliferation, apoptosis,
migration, differentiation [53–55]. Disrupted or dysregu-
lated JAK-STAT pathway result in immune deficiency
syndromes and cancers [56]. Gain-of-function mutations in
IL7R is one of the other mutations that activate the JAK-
STAT signaling pathway and have been identified in
patients with ALL. Activating mutations in IL7R are com-
monly found in T and B cell ALL and are frequently placed
in the transmembrane domain [20, 57, 58]. IL7R is essential
for normal lymphoid development [59]. IL7R heterodi-
merizes either with interleukin 2 receptor subunit gamma
(IL2RG) to form a receptor to IL-7 or with CRLF2 to form
a receptor to TSLP [60, 61]. Activating mutations in IL7R
lead to dimerization and constitutive activation of the IL-7
receptor and resulting in cytokine independent activation
of the downstream signaling pathways including JAK–STAT
signaling pathway [57].
Conclusions
Obviously genome sequencing has revolutionized our
knowledge of the genomic basis of ALL. These techniques
helped us to identify new clinically important ALL subtypes
and leukaemogenic alterations, which have led to a better
risk stratification and will lead to improvement of patient-
directed or individualized therapy for every patient. How-
ever, more comprehensively sequenced ALL genome is
required to fully understand all somatic genetic alteration of
ALL that incorporate to treatment failure and disease
relapse.
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